NLS Collaboration

The LifeFactFuture consortium includes the University of Turku, the University of Helsinki, Orion, some of Finland’s leading life science manufacturers, and data and technology companies. The project, led by the University of Turku and for which Business Finland recently granted EUR 11.7 million funding, seeks to enhance advanced pharmaceutical and life science manufacturing in Finland. […]

The status of national strategies and a common Nordic roadmap. Rare disease companies struggle with a range of challenges, one of which is how to balance funding R&D with a small market size. Healthcare systems and societies also face a balancing act when it comes to rare diseases – between innovation and accessibility. Having a […]

People with rare diseases and disabilities face common challenges in the Nordic region. Small populations in each individual country make it tricky to set up treatment protocols and gather data, for example, and Nordic cooperation is being highlighted as a possible answer to many of the issues. It is the rare that unites, and only […]

On May 24th, five Nordic university hospitals signed a Memorandum of Understanding (MoU) to inaugurate the new alliance, The Nordic University Hospital Alliance (NUHA). The goal is to strengthen relationships and collaborations between the hospitals and establish a strategy for addressing healthcare challenges in the Nordic region. The alliance aims to enhance quality and foster […]

The initiative will provide funding to maintain high-quality health databases in the country and to support research that uses this data to advance understanding of cardiometabolic diseases (CMD). The aim is to ensure that valuable data remains both secure and accessible for future research, strengthening the CMD research environment in Denmark, states Novo Nordisk Foundation […]

IRLAB Therapeutics has  announced a collaboration agreement with the McQuade Center for Strategic Research and Development (MSRD), a member of the global Otsuka family of pharmaceutical companies. IRLAB and MSRD will exclusively collaborate in the development of IRLAB’s novel drug candidate IRL757 for the potential treatment of apathy in Parkinson’s and other neurological conditions through […]